Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Rufinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rufinamide SCHEMBL20769779 | 1.00 | CA5A (1.00) | CA5AKLKB1CYP2C19SCDALDH1A1 | |
| Rufinamide SCHEMBL17372728 | 0.99 | CA5A (0.97) | CA5AKLKB1CYP2C19SCDALDH1A1 | |
| Rufinamide SCHEMBL2594153 | 0.93 | CA5A (0.87) | CA5AKLKB1CYP2C19SCDALDH1A1 | |
| SCHEMBL9857399 | 0.91 | CA5A (0.82) | CA5AKLKB1CYP2C19SCDALDH1A1 | |
| SCHEMBL15699133 | 0.91 | CA5A (0.82) | CA5AKLKB1CYP2C19SCDALDH1A1 | |
| SCHEMBL460913 | 0.87 | CA5A (0.76) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL15838652 | 0.86 | CA5A (0.75) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL6738882 | 0.85 | CA5A (0.74) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL460954 | 0.85 | CA5A (0.74) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL9857834 | 0.85 | CA5A (0.73) | CA5AKLKB1CYP2C19SCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3824 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | claimed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4687835-A1 | A BIPHASIC LIQUID PHARMACEUTICAL COMPOSITION OF AN ANTICONVULSANT DRUG AND THE PROCESS OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-12533345-B2 | Rufinamide for use in the treatment of myotonia | AARHUS UNIVERSITET (DK) | 2026-01-27 | — | — | US | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-6156775-A | Use of fluorinated triazoles in treating affective and attention disorders | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | claimed |
| WO-2000051577-A2 | USE OF FLUORINATED TRIAZOLES FOR TREATING PAIN AND AFFECTIVE OR ATTENTION DISORDERS | NOVARTIS AG (CH) | 2000-09-08 | — | — | WO | claimed |
| EP-0994863-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | Novartis AG (CH) | 2000-04-26 | — | — | EP | claimed |
| EP-0994864-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | Novartis-Erfindungen Verwaltungsgesellschaft m.b.H. (AT) | 2000-04-26 | — | — | EP | claimed |
| US-6054471-A | Use of fluorinated triazoles in treating neuropathic pain | NOVARTIS AG (CH) | 2000-04-25 | — | — | US | claimed |
| WO-1998056773-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | NOVARTIS AG (CH) | 1998-12-17 | — | — | WO | claimed |
| WO-1998056772-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3--TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | NOVARTIS AG (CH) | 1998-12-17 | — | — | WO | claimed |
| EP-0199262-B1 | FLUORINATED BENZYL TRIAZOLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-02-27 | — | — | EP | claimed |
| US-4789680-A | Aralkyltriazole compounds | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | claimed |
| EP-0199262-A2 | Fluorinated benzyl triazole compounds | CIBA-GEIGY AG (CH) | 1986-10-29 | — | — | EP | claimed |